Semantic Scholar uses AI to extract papers important to this topic.
Increasing bacterial resistance to antibiotics is a worldwide ongoing issue. Urgent need for new antibacterial agents has… Expand Inhalational anthrax is a highly lethal infection caused by Bacillus anthracis and a serious bioterrorism threat. Protective… Expand Objective: To review the safety and efficacy of obiltoxaximab, a monoclonal antibody indicated for the treatment of Bacillus… Expand Obiltoxaximab, a monoclonal antibody against protective antigen (PA), is approved for treatment of inhalational anthrax under the… Expand ABSTRACT The recommended management of inhalational anthrax, a high-priority bioterrorist threat, includes antibiotics and… Expand Obiltoxaximab (Anthim®, ETI-204) is a monoclonal antibody that is being developed by Elusys Therapeutics and the US Department of… Expand ABSTRACT The Centers for Disease Control and Prevention recommend adjunctive antitoxins when systemic anthrax is suspected… Expand ABSTRACT Inhalational anthrax has high mortality even with antibiotic treatment, and antitoxins are now recommended as an adjunct… Expand PURPOSE
This report describes the safety, immunogenicity, and pharmacokinetic results of obiltoxaximab treatment in healthy… Expand A new agent used to treat and prevent inhalational anthrax has received FDA approval.
Obiltoxaximab, marketed as Anthim, is… Expand